03/11/2026
A legislative bill was passed in the state of Indiana in March (SB282). This bill had a significant amount of financial support and backing by a large pharmaceutical company.
I’ve decided to talk about this, because someone needs to.
Before opening Adorn, I worked in a capacity in which I saw how legislation moved. What it walks like, talks like, and what is buried beneath the surface. I have also personally gone through five audits by licensing and accreditation bodies. I understand the full potential of this bill, and I want to help others be prepared.
Everyone who believes this is just checking a couple boxes… is mistaken.
This bill wears a David mask, but has Goliath potential to forever change the landscape of Functional Medicine and Aesthetics.
SB282 initially reads like tighter MedSpa regulation(s), which quite honestly - are needed to some degree.
But that is not the goal of this bill.
Pharmaceutical companies don’t lobby for bills where they don’t have a vested financial interest. They lobby for bills where they intend to use their full legal authority and power to make sure their bottom line is protected, where they do.
This bill takes aim at compounded GLP-1 medications, and those prescribing them. All MedSpas must comply, but those dispensing compounded GLP-1s as part of their practice will undoubtedly be the primary focus.
I have decided to start speaking about this on the Adorn page. Offering some insights and tips for what you need to be prepared for next, for what isn’t explicitly stated in this bill.
I would encourage every aesthetic and functional medicine provider in the state to quickly educate yourself on what is happening with this bill.
SB282 isn’t the end. It’s the beginning, and more will follow.
I will begin sharing consents, inter-office policies, and other helpful tools and tips here for other aesthetics providers to get prepared starting next week.
I am working with other Providers throughout the state on this as well.
-Lt
